Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease

被引：6

作者：

Fukada, Atsuki ^{[1
]}

Fujisawa, Tomoyuki ^{[1
]}

Hozumi, Hironao ^{[1
]}

Koda, Keigo ^{[2
]}

Akamatsu, Taisuke ^{[3
]}

Oyama, Yoshiyuki ^{[4
]}

Satake, Yasuomi ^{[5
]}

Niwa, Mitsuru ^{[6
]}

Kaida, Yusuke ^{[7
]}

Matsuda, Hiroyuki ^{[8
]}

Yokomura, Koshi ^{[9
]}

Koshimizu, Naoki ^{[10
]}

Toyoshima, Mikio ^{[2
]}

Imokawa, Shiro ^{[11
]}

Hashimoto, Dai ^{[12
]}

Yoshida, Akira ^{[13
]}

Gono, Takahisa ^{[13
]}

Kuwana, Masataka ^{[13
]}

Yamano, Yasuhiko ^{[14
]}

Kondoh, Yasuhiro ^{[14
]}

Yamashita, Keita ^{[1
]}

Maekawa, Masato ^{[1
]}

Mori, Kazutaka ^{[15
]}

Inoue, Yusuke ^{[1
]}

Yasui, Hideki ^{[1
]}

Suzuki, Yuzo ^{[1
]}

Karayama, Masato ^{[1
]}

Furuhashi, Kazuki ^{[1
]}

Enomoto, Noriyuki ^{[1
]}

Inui, Naoki ^{[1
]}

Suda, Takafumi ^{[1
]}

机构：

[1] Hamamatsu Univ Sch Med, Hamamatsu, Japan

[2] Hamamatsu Rosai Hosp, Hamamatsu, Japan

[3] Shizuoka Prefectural Gen Hosp, Shizuoka, Japan

[4] Shizuoka Saiseikai Gen Hosp, Shizuoka, Japan

[5] Shizuoka City Shimizu Hosp, Shizuoka, Japan

[6] Hamamatsu Med Ctr, Hamamatsu, Japan

[7] Enshu Hosp, Hamamatsu, Japan

[8] Japanese Red Cross Shizuoka Hosp, Shizuoka, Japan

[9] Seirei Mikatahara Gen Hosp, Hamamatsu, Japan

[10] Fujieda Municipal Gen Hosp, Fujieda, Shizuoka, Japan

[11] Iwata City Hosp, Iwata, Japan

[12] Seirei Hamamatsu Gen Hosp, Hamamatsu, Japan

[13] Nippon Med Sch, Grad Sch Med, Tokyo, Japan

[14] Tosei Gen Hosp, Seto, Japan

[15] Shizuoka City Shimizu Hosp, Dept, Shizuoka, Japan

来源：

ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷 / 05期

基金：

日本学术振兴会;

关键词：

IDIOPATHIC INFLAMMATORY MYOPATHIES; ANTI-MDA5; ANTIBODY; POLYMYOSITIS; AUTOANTIBODIES; MYOSITIS; FEATURES;

D O I：

10.1002/art.42785

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ObjectiveInterferon-lambda 3 (IFN lambda 3) is a cytokine with antiviral functions on barrier surfaces, and it is associated with disease activity in autoimmune diseases. This study assessed the clinical significance of serum IFN lambda 3 levels in polymyositis/dermatomyositis (PM/DM)-associated interstitial lung disease (ILD). MethodsWe measured serum IFN lambda 3 levels in 221 patients with PM/DM-ILD (155 in the derivation cohort, 66 in the validation cohort) and 38 controls. We evaluated factors associated with mortality risk among 79 patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive DM-ILD. ResultsSerum IFN lambda 3 levels at diagnosis were significantly higher in patients with PM/DM-ILD than in healthy controls. Remarkably, serum IFN lambda 3 levels were specifically increased in patients with anti-MDA5 antibody-positive DM-ILD in both the derivation and validation cohorts. In anti-MDA5 antibody-positive DM-ILD, patients with high IFN lambda 3 levels (>120 pg/mL) had significantly lower survival rates than those with low IFN lambda 3 levels (<= 120 pg/mL). A multivariate analysis revealed that high IFN lambda 3 levels, as well as old age and low Pao2, were significantly associated with poor prognoses in patients with anti-MDA5 antibody-positive DM-ILD. In a classification analysis of patients with anti-MDA5 antibody-positive DM-ILD based on age, IFN lambda 3 level, and Pao2, patients with old age (>53 years), high IFN lambda 3 levels (>120 pg/mL), and low Pao2 (<75 mm Hg) had the worst survival. In lung pathologic analyses, IFN lambda 3-positive staining was observed in macrophages, airway epithelial cells, the pleural region, and intrapulmonary veins in patients with anti-MDA5 antibody-positive DM-ILD. ConclusionSerum IFN lambda 3 is a promising biomarker for identifying patients at high risk of poor outcomes in anti-MDA5 antibody-positive DM-ILD.

引用

页码：796 / 805

页数：10

共 39 条

[1] Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases [J].

Allenbach, Yves ;

Uzunhan, Yurdagul ;

Toquet, Segolene ;

Leroux, Gaelle ;

Gallay, Laure ;

Marquet, Alicia ;

Meyer, Alain ;

Guillaud, Constance ;

Limal, Nicolas ;

Gagnadoux, Frederic ;

Hervier, Baptiste ;

Borie, Raphael ;

Deligny, Christophe ;

Terrier, Benjamin ;

Berezne, Alice ;

Audia, Sylvain ;

Champtiaux, Nicolas ;

Devilliers, Herve ;

Voermans, Nicol ;

Diot, Elizabeth ;

Servettaz, Amelie ;

Marhadour, Thierry ;

Castelain, Vincent ;

Humbert, Sebastien ;

Blanchard-Delaunay, Claire ;

Tieulie, Nathalie ;

Charles, Pierre ;

Gerin, Magdalena ;

Mekinian, Arsene ;

Priou, Pascaline ;

Meurice, Jean Claude ;

Tazi, Abdellatif ;

Cottin, Vincent ;

Miyara, Makoto ;

Grange, Benjamin ;

Israel-Biet, Dominique ;

Phin-Huynh, Sophie ;

Bron, Camille ;

De Saint Martin, Luc ;

Fabien, Nicole ;

Mariampillai, Kuberaka ;

Nunes, Hilario ;

Benveniste, Olivier .

NEUROLOGY, 2020, 95 (01) :E70-E78

[2] Type III Interferons in Systemic Lupus Erythematosus Association Between Interferon λ3, Disease Activity, and Anti-Ro/SSA Antibodies [J].

Amezcua-Guerra, Luis M. ;

Marquez-Velasco, Ricardo ;

Chavez-Rueda, Adriana K. ;

Castillo-Martinez, Diana ;

Masso, Felipe ;

Paez, Araceli ;

Colin-Fuentes, Juan ;

Bojalil, Rafael .

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2017, 23 (07) :368-375

[3] Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection [J].

Aoki, Yoshihiko ;

Sugiyama, Masaya ;

Murata, Kazumoto ;

Yoshio, Sachiyo ;

Kurosaki, Masayuki ;

Hashimoto, Satoru ;

Yatsuhashi, Hiroshi ;

Nomura, Hideyuki ;

Kang, Jong-Hon ;

Takeda, Tsutomu ;

Naito, Shigeko ;

Kimura, Tatsuji ;

Yamagiwa, Yoko ;

Korenaga, Masaaki ;

Imamura, Masatoshi ;

Masaki, Naohiko ;

Izumi, Namiki ;

Kage, Masayoshi ;

Mizokami, Masashi ;

Kanto, Tatsuya .

JOURNAL OF GASTROENTEROLOGY, 2015, 50 (08) :894-902

[4] POLYMYOSITIS AND DERMATOMYOSITIS .2. [J].

BOHAN, A ;

PETER, JB .

NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (08) :403-407

[5] Type III interferons disrupt the lung epithelial barrier upon viral recognition [J].

Broggi, Achille ;

Ghosh, Sreya ;

Sposito, Benedetta ;

Spreafico, Roberto ;

Balzarini, Fabio ;

Lo Cascio, Antonino ;

Clementi, Nicola ;

De Santis, Maria ;

Mancini, Nicasio ;

Granucci, Francesca ;

Zanoni, Ivan .

SCIENCE, 2020, 369 (6504) :706-+

[6] Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion [J].

Broggi, Achille ;

Granucci, Francesca ;

Zanoni, Ivan .

JOURNAL OF EXPERIMENTAL MEDICINE, 2020, 217 (01)

[7] Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese [J].

Chen, Ji-Yih ;

Wang, Chin-Man ;

Chen, Tai-Di ;

Wu, Yeong-Jian Jan ;

Lin, Jing-Chi ;

Lu, Ling Ying ;

Wu, Jianming .

ARTHRITIS RESEARCH & THERAPY, 2018, 20

[8] What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19? [J].

De Lorenzis, Enrico ;

Natalello, Gerlando ;

Gigante, Laura ;

Verardi, Lucrezia ;

Bosello, Silvia Laura ;

Gremese, Elisa .

AUTOIMMUNITY REVIEWS, 2020, 19 (11)

[9] Human interferon-λ3 is a potent member of the type III interferon family [J].

Dellgren, C. ;

Gad, H. H. ;

Hamming, O. J. ;

Melchjorsen, J. ;

Hartmann, R. .

GENES AND IMMUNITY, 2009, 10 (02) :125-131

[10]

Fujisawa T, 2005, J RHEUMATOL, V32, P58

← 1 2 3 4 →